Biomarkers that predict the clinical onset of Alzheimer's disease (AD) enable the
identification of individuals in the early, preclinical stages of the disease. Detecting AD at this …

Amyloid plaques and tau tangles are the hallmark pathologic features of Alzheimer's
disease (AD). Traditionally, these changes are identified in vivo via cerebrospinal fluid (CSF) …

Background It is not fully established whether plasma β-amyloid (Aβ) 42/Aβ40 and
phosphorylated Tau181 (p-Tau181) can effectively detect Alzheimer's disease (AD) …

INTRODUCTION MicroRNAs are short non‐coding RNAs that control proteostasis at the
systems level and are emerging as potential prognostic and diagnostic biomarkers for …

Biological and clinical heterogeneity is a major challenge in research for developing new
treatments for Alzheimer's disease (AD). AD may be defined by its amyloid beta and tau …

Background and Objectives To compare the diagnostic performance of an immunoassay for
plasma concentrations of phosphorylated tau (p-tau) 217 with visual assessments of fluorine …

Recent developments in fluid and imaging biomarkers that reflect the key pathological
hallmarks of Alzheimer's disease (AD)—deposits of extracellular amyloid-β (Aβ) and …

INTRODUCTION Plasma phosphorylated tau (p‐tau) 217 is a promising biomarker for
Alzheimer's disease (AD) diagnosis, but its clinical implementation remains challenging. We …

Plasma p-tau217 and Tau-PET are strong prognostic biomarkers in Alzheimers disease
(AD), but their relative performance in predicting future cognitive decline among cognitively …

One of the most familiar types of disease is Alzheimer's disease (AD) and it mainly impacts
people over the age limit of 60. AD causes irreversible brain damage in humans. It is difficult …